Related Experiment Video

Updated: Nov 10, 2025

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance
09:48

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance

Published on: February 17, 2023

3.1K

Exosomes and Obesity-Related Insulin Resistance

Li-Min Lei1, Xiao Lin2, Feng Xu1

  • 1National Clinical Research Center for Metabolic Disease, Hunan Provincial Key Laboratory of Metabolic Bone Diseases, Department of Endocrinology and Metabolism, The Second Xiangya Hospital, Central South University, Changsha, China.

Frontiers in Cell and Developmental Biology
|April 5, 2021
PubMed

Insights

Exosomes play a key role in developing obesity-related insulin resistance. Further research into exosomes could lead to new diagnostic and therapeutic strategies for insulin resistance and associated diseases.

Area of Science:

  • Cell Biology
  • Metabolic Diseases
  • Biochemistry

Background:

  • Exosomes are crucial extracellular vesicles mediating intercellular communication.
  • Insulin resistance is a pathological state implicated in type 2 diabetes mellitus, gestational diabetes mellitus, and Alzheimer's disease.
  • Obesity is a significant risk factor contributing to the development of insulin resistance.

Purpose of the Study:

  • To review recent advancements in understanding the role of exosomes in insulin resistance.
  • To specifically focus on the connection between exosomes and obesity-related insulin resistance.
  • To explore the potential of exosomes in the diagnosis and treatment of insulin resistance.

Main Methods:

  • Literature review of current research on exosomes and insulin resistance.
  • Analysis of studies focusing on obesity-induced insulin resistance.
  • Synthesis of findings regarding exosome cargo and function in metabolic regulation.

Main Results:

  • Exosomes facilitate the transfer of bioactive molecules that influence insulin sensitivity.
  • Obesity promotes alterations in exosome biogenesis and cargo, contributing to insulin resistance.
  • Evidence suggests exosomes are key players in the progression of obesity-related insulin resistance.

Conclusions:

  • Exosomes are significantly involved in the pathogenesis of obesity-related insulin resistance.
  • Exosomes hold promise as biomarkers for diagnosing insulin resistance.
  • Exosomes represent a potential therapeutic target for managing insulin resistance and related metabolic disorders.
Keywords:
exosomesinflammationinsulin resistancemesenchymal stem cellobesity

More Related Videos

Author Spotlight: Semi-Automated Isolation of the Stromal Vascular Fraction from Murine White Adipose Tissue Using a Tissue Dissociator06:08

Author Spotlight: Semi-Automated Isolation of the Stromal Vascular Fraction from Murine White Adipose Tissue Using a Tissue Dissociator

Published on: May 19, 2023

2.6K
An Adipocyte Cell Culture Model to Study the Impact of Protein and Micro-RNA Modulation on Adipocyte Function09:20

An Adipocyte Cell Culture Model to Study the Impact of Protein and Micro-RNA Modulation on Adipocyte Function

Published on: May 4, 2021

4.0K

Related Concept Videos

Insulin Secretory Vesicles01:05

Insulin Secretory Vesicles

Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
6.1K
Overview of Exosomes01:36

Overview of Exosomes

Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
3.1K
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
888
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
64
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.9K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
79